Annual report
4583.TEDINET S100XUJT
Period2025-01-01 → 2025-12-31
Filed2026-03-27
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 76
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥593m | 2025-01-01 → 2025-12-31 | Standalone | Net sales |
| Revenue | ¥781m | 2024-01-01 → 2024-12-31 | Standalone | Net sales |
| Revenue | ¥682m | 2023-01-01 → 2023-12-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥631m | 2022-01-01 → 2022-12-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥713m | 2021-01-01 → 2021-12-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥980m | 2025-01-01 → 2025-12-31 | Standalone | Operating income |
| Operating income | −¥1.0bn | 2024-01-01 → 2024-12-31 | Standalone | Operating income |
| Ordinary income | −¥989m | 2025-01-01 → 2025-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.0bn | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income |
| Ordinary income | −¥1.2bn | 2023-01-01 → 2023-12-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.2bn | 2022-01-01 → 2022-12-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.3bn | 2021-01-01 → 2021-12-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥980m | 2025-01-01 → 2025-12-31 | Standalone | Income before income taxes |
| Profit before tax | −¥1.0bn | 2024-01-01 → 2024-12-31 | Standalone | Income before income taxes |
| Net income | −¥983m | 2025-01-01 → 2025-12-31 | Standalone | Profit loss |
| Net income | −¥1.0bn | 2024-01-01 → 2024-12-31 | Standalone | Profit loss |
| Net income | −¥1.2bn | 2023-01-01 → 2023-12-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥1.2bn | 2022-01-01 → 2022-12-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥1.5bn | 2021-01-01 → 2021-12-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.7bn | at 2025-12-31 | Standalone | Assets |
| Total assets | ¥2.5bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥1.8bn | at 2023-12-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.2bn | at 2022-12-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.3bn | at 2021-12-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥605m | at 2025-12-31 | Standalone | Liabilities |
| Total liabilities | ¥549m | at 2024-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.1bn | at 2025-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.9bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.2bn | at 2023-12-31v | Standalone | Net assets |
| Net assets / equity | ¥1.8bn | at 2022-12-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.9bn | at 2021-12-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.2bn | at 2025-12-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.1bn | at 2024-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.2bn | at 2025-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥2.1bn | at 2024-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2023-12-31v | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.7bn | at 2022-12-31v | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.8bn | at 2021-12-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥936m | 2025-01-01 → 2025-12-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.0bn | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.1bn | 2023-01-01 → 2023-12-31v | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.2bn | 2022-01-01 → 2022-12-31v | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.1bn | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥55m | 2025-01-01 → 2025-12-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | ¥173,000 | 2023-01-01 → 2023-12-31v | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥35m | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥133m | 2025-01-01 → 2025-12-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.7bn | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥667m | 2023-01-01 → 2023-12-31v | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.1bn | 2022-01-01 → 2022-12-31v | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥271m | 2021-01-01 → 2021-12-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-14.47 | 2025-01-01 → 2025-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-17.54 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-24.62 | 2023-01-01 → 2023-12-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-28.26 | 2022-01-01 → 2022-12-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-36.74 | 2021-01-01 → 2021-12-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥16.18 | at 2025-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥28.53 | at 2024-12-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥21.66 | at 2023-12-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥36.7 | at 2022-12-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥45.55 | at 2021-12-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 64.1% | at 2025-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.4% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.1% | at 2023-12-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.2% | at 2022-12-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 79.4% | at 2021-12-31d | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 68,453,800 | at 2025-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 66,969,000 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 52,640,200 | at 2023-12-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 48,423,500 | at 2022-12-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 40,781,500 | at 2021-12-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 49 | at 2025-12-31 | Standalone | Number of employees |
| Employees | 47 | at 2024-12-31 | Standalone | Number of employees |
| Employees | 51 | at 2023-12-31v | Standalone | Number of employees |
| Employees | 49 | at 2022-12-31v | Standalone | Number of employees |
| Employees | 49 | at 2021-12-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 22
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-12-31 | −¥559m |
| Drug Discovery And Developmentreportable segment | segment profit | 2025-01-01 → 2025-12-31 | −¥777m |
| Drug Discovery Supportreportable segment | depreciation | 2025-01-01 → 2025-12-31 | ¥4m |
| Drug Discovery Supportreportable segment | revenue | 2025-01-01 → 2025-12-31 | ¥593m |
| Drug Discovery Supportreportable segment | revenue external | 2025-01-01 → 2025-12-31 | ¥593m |
| Drug Discovery Supportreportable segment | segment profit | 2025-01-01 → 2025-12-31 | ¥356m |
| —segment total | employees | at 2025-12-31 | 39 pure |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-01-01 → 2025-12-31 | ¥4m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-01-01 → 2025-12-31 | ¥593m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-01-01 → 2025-12-31 | ¥593m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-01-01 → 2025-12-31 | −¥421m |
| Reconciling Itemsreconciling | depreciation | 2024-01-01 → 2024-12-31 | ¥1m |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-12-31 | −¥527m |
| Drug Discovery And Developmentreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥203m |
| Drug Discovery And Developmentreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥203m |
| Drug Discovery And Developmentreportable segment | segment profit | 2024-01-01 → 2024-12-31 | −¥814m |
| Drug Discovery Supportreportable segment | revenue | 2024-01-01 → 2024-12-31 | ¥578m |
| Drug Discovery Supportreportable segment | revenue external | 2024-01-01 → 2024-12-31 | ¥578m |
| Drug Discovery Supportreportable segment | segment profit | 2024-01-01 → 2024-12-31 | ¥310m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-01-01 → 2024-12-31 | ¥781m |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-01-01 → 2024-12-31 | ¥781m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-01-01 → 2024-12-31 | −¥504m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 832
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report non consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)太 陽 有 限 責 任 監 査 法 人 | |
| Cpa1 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)田 村 知 弘 | |
| Cpa2 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)櫻 井 純 一 | |
| Key audit matters non consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam non consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)バイオシミラーの共同開発における開発支援契約に関する収益認識 | |
| Description including reason kam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Auditors response kam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior4YearDuration_NonConsolidatedMember | 712932000 | JPY |
| Net sales (5-year summary) | Prior3YearDuration_NonConsolidatedMember | 630815000 | JPY |
| Net sales (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 682464000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 780809000 | JPY |
| Net sales (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 593290000 | JPY |
| Ordinary income loss (5-year summary) | Prior4YearDuration_NonConsolidatedMember | -1329312000 | JPY |
| Ordinary income loss (5-year summary) | Prior3YearDuration_NonConsolidatedMember | -1243838000 | JPY |
| Ordinary income loss (5-year summary) | Prior2YearDuration_NonConsolidatedMember | -1217240000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration_NonConsolidatedMember | -1019210000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYearDuration_NonConsolidatedMember | -989127000 | JPY |
| Net income loss (5-year summary) | Prior4YearDuration_NonConsolidatedMember | -1479895000 | JPY |
| Net income loss (5-year summary) | Prior3YearDuration_NonConsolidatedMember | -1242871000 | JPY |
| Net income loss (5-year summary) | Prior2YearDuration_NonConsolidatedMember | -1220018000 | JPY |
| Net income loss (5-year summary) | Prior1YearDuration_NonConsolidatedMember | -1020776000 | JPY |
| Net income loss (5-year summary) | CurrentYearDuration_NonConsolidatedMember | -982779000 | JPY |
| Equity in earnings losses of affiliates if equity method is applied (5-year summary) | Prior4YearDuration_NonConsolidatedMember | － | JPY |
| Equity in earnings losses of affiliates if equity method is applied (5-year summary) | Prior3YearDuration_NonConsolidatedMember | － | JPY |
| Equity in earnings losses of affiliates if equity method is applied (5-year summary) | Prior2YearDuration_NonConsolidatedMember | － | JPY |
| Equity in earnings losses of affiliates if equity method is applied (5-year summary) | Prior1YearDuration_NonConsolidatedMember | － | JPY |
| Equity in earnings losses of affiliates if equity method is applied (5-year summary) | CurrentYearDuration_NonConsolidatedMember | － | JPY |
| Capital stock (5-year summary) | Prior4YearInstant_NonConsolidatedMember | 1515929000 | JPY |
| Capital stock (5-year summary) | Prior3YearInstant_NonConsolidatedMember | 2097017000 | JPY |
| Capital stock (5-year summary) | Prior2YearInstant_NonConsolidatedMember | 2388422000 | JPY |
| Capital stock (5-year summary) | Prior1YearInstant_NonConsolidatedMember | 995525000 | JPY |
| Capital stock (5-year summary) | CurrentYearInstant_NonConsolidatedMember | 1085523000 | JPY |
| Total number of issued shares (5-year summary) | Prior4YearInstant_NonConsolidatedMember | 40781500 | |
| Total number of issued shares (5-year summary) | Prior3YearInstant_NonConsolidatedMember | 48423500 | |
| Total number of issued shares (5-year summary) | Prior2YearInstant_NonConsolidatedMember | 52640200 | |
| Total number of issued shares (5-year summary) | Prior1YearInstant_NonConsolidatedMember | 66969000 | |
| Total number of issued shares (5-year summary) | CurrentYearInstant_NonConsolidatedMember | 68453800 | |
| Net assets (5-year summary) | Prior4YearInstant_NonConsolidatedMember | 1893049000 | JPY |
| Net assets (5-year summary) | Prior3YearInstant_NonConsolidatedMember | 1790746000 | JPY |
| Net assets (5-year summary) | Prior2YearInstant_NonConsolidatedMember | 1157723000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant_NonConsolidatedMember | 1920303000 | JPY |
| Net assets (5-year summary) | CurrentYearInstant_NonConsolidatedMember | 1122064000 | JPY |
| Total assets (5-year summary) | Prior4YearInstant_NonConsolidatedMember | 2339439000 | JPY |
| Total assets (5-year summary) | Prior3YearInstant_NonConsolidatedMember | 2215470000 | JPY |
| Total assets (5-year summary) | Prior2YearInstant_NonConsolidatedMember | 1751454000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 13 of 13 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |